# A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

> **NCT03529773** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 1235 (actual)

## Conditions studied

- Respiratory Tract Infections

## Interventions

- **BIOLOGICAL:** Formulation A
- **BIOLOGICAL:** Formulation B
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03529773
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-18
- **Primary completion:** 2019-11-20
- **Final completion:** 2020-12-28
- **Target enrollment:** 1235 (ACTUAL)
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03529773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03529773, "A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03529773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*